Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | VNN1 | O95497 | 6/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229379 | 0.95 | KCNH2 (0.43) | KCNH2VNN1PARP10PARP15PARP2 | |
| SCHEMBL5228154 | 0.91 | CYP3A4 (0.40) | KCNH2VNN1PARP10PARP15PARP2 | |
| SCHEMBL509089 | 0.91 | KCNH2 (0.47) | KCNH2VNN1PARP10PARP15PARP2 | |
| SCHEMBL5226676 | 0.89 | VNN1 (0.47) | VNN1PARP10PARP15PARP2OPRM1 | |
| SCHEMBL5226693 | 0.82 | KCNH2 (0.45) | KCNH2VNN1CYP2C9 | |
| SCHEMBL509760 | 0.82 | CYP3A4 (0.39) | KCNH2VNN1OPRM1OPRD1OPRK1 | |
| SCHEMBL5228148 | 0.80 | KCNH2 (0.53) | KCNH2CACNA1GCACNA1BCYP2C9 | |
| SCHEMBL509241 | 0.80 | KCNH2 (0.45) | KCNH2CYP2C9 | |
| SCHEMBL508578 | 0.79 | KCNH2 (0.53) | KCNH2CACNA1GCACNA1BCYP2C9 | |
| SCHEMBL5228111 | 0.79 | KCNH2 (0.53) | KCNH2VNN1CACNA1GCACNA1BCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | KCNH2 3503/4885VNN1 2419/4885PARP10 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.